The MS Commissioning Pathway May Help Manage Multiple Sclerosis


Research has shown that multiple sclerosis (MS) is "the most common cause of neurological disability in young adults."

Research has shown that multiple sclerosis (MS) is “the most common cause of neurological disability in young adults.” Because a majority of patients are diagnosed with MS between ages 20-40 years, they require special care for a much longer period of time. In order to maintain a successful treatment plan, neurologists and other care providers need to work together. Therefore, the UK-based charity MS Trust, which focuses on helping people with MS “live their lives to the [fullest]”, launched MS Commissioning Pathway yesterday. The pathway was “designed to simplify the process (what process?) and enable commissioners to provide effective commissioning (what does this mean?) for MS” and “provides information on the requirements for MS commissioning from diagnosis to death.”

On the MS commissioning pathway website, neurologists can learn how to use the pathway by reviewing the step-by-step PowerPoint presentation which explains each section, view a user’s guide, download supplemental information, and suggestions on how to apply it into practice. Nicola Russell, Director of Services of the MS Trust, said, “This pathway has been produced following consultation with major parties and we are hopeful that it will be the key to successful commissioning in the future.”

Although the program was designed for UK providers, US-based neurologists may find it a useful tool to help treat their MS patients, as it helps determine when it’s best to deliver “prompt and appropriate interventions.”

How does this apply to US neurologists? Does the MS Commissioning Pathway call for certain actions and considerations that apply only to the practice of medicine in the UK?

Related Article on HCPLive:

Fampridine Aids Mobility in MS Patients

Related Videos
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
© 2024 MJH Life Sciences

All rights reserved.